title: Chemotherapy plus RA233 in the treatment of oat cell lung cancer.
abstract: One hundred and one patients with oat (small) cell lung cancer have been treated with CAVE [Cytoxan, Adriamycin, Vincristine, and etoposide (VP-16)] chemotherapy +/- RA233 (a platelet-inhibiting agent). There was no difference in disease-free interval, pattern of relapse, or survival between groups.
authors.affiliation: Department of Medicine, Milton S. Hershey Medical Center, Hershey, PA 17033.
authors.forename: A
authors.initials: A
authors.lastname: Lipton
authors.forename: H A
authors.initials: HA
authors.lastname: Harvey
authors.forename: B
authors.initials: B
authors.lastname: Walker
authors.forename: R
authors.initials: R
authors.lastname: Dixon
authors.forename: D
authors.initials: D
authors.lastname: Valdivia
authors.forename: S
authors.initials: S
authors.lastname: Barnes
authors.forename: R
authors.initials: R
authors.lastname: Gordon
authors.forename: D
authors.initials: D
authors.lastname: White-Hershey
authors.forename: M J
authors.initials: MJ
authors.lastname: Bartholomew
authors.forename: N
authors.initials: N
authors.lastname: Warzawski
mesh_terms: D000206:Actuarial Analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D003520:Cyclophosphamide / Q000008:administration & dosage; D004311:Double-Blind Method; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009012:Mopidamol / Q000627:therapeutic use*; D011034:Podophyllotoxin / Q000008:administration & dosage; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*; D011897:Random Allocation; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D011743:Pyrimidines; D009012:Mopidamol; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011034:Podophyllotoxin